311 related articles for article (PubMed ID: 33201212)
1. Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.
Kalla R; Adams AT; Bergemalm D; Vatn S; Kennedy NA; Ricanek P; Lindstrom J; Ocklind A; Hjelm F; Ventham NT; Ho GT; Petren C; Repsilber D; Söderholm J; Pierik M; D'Amato M; Gomollón F; Olbjorn C; Jahnsen J; Vatn MH; Halfvarson J; Satsangi J
J Crohns Colitis; 2021 May; 15(5):699-708. PubMed ID: 33201212
[TBL] [Abstract][Full Text] [Related]
2. Whole Blood Profiling of T-cell-Derived microRNA Allows the Development of Prognostic models in Inflammatory Bowel Disease.
Kalla R; Adams AT; Ventham NT; Kennedy NA; White R; Clarke C; Ivens A; Bergemalm D; Vatn S; Lopez-Jimena B; ; Ricanek P; Vatn MH; Söderholm JD; Gomollón F; Nowak JK; Jahnsen J; Halfvarson J; McTaggart S; Ho GT; Buck A; Satsangi J
J Crohns Colitis; 2020 Dec; 14(12):1724-1733. PubMed ID: 32598439
[TBL] [Abstract][Full Text] [Related]
3. Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.
Kalla R; Kennedy NA; Ventham NT; Boyapati RK; Adams AT; Nimmo ER; Visconti MR; Drummond H; Ho GT; Pattenden RJ; Wilson DC; Satsangi J
Am J Gastroenterol; 2016 Dec; 111(12):1796-1805. PubMed ID: 27596694
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Systemic Epigenetic Alterations in Inflammatory Bowel Disease: Defining Geographical, Genetic and Immune-Inflammatory influences on the Circulating Methylome.
Kalla R; Adams AT; Nowak JK; Bergemalm D; Vatn S; Ventham NT; Kennedy NA; Ricanek P; Lindstrom J; ; Söderholm J; Pierik M; D'Amato M; Gomollón F; Olbjørn C; Richmond R; Relton C; Jahnsen J; Vatn MH; Halfvarson J; Satsangi J
J Crohns Colitis; 2023 Mar; 17(2):170-184. PubMed ID: 36029471
[TBL] [Abstract][Full Text] [Related]
5. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists.
Guo A; Ross C; Chande N; Gregor J; Ponich T; Khanna R; Sey M; Beaton M; Yan B; Kim RB; Wilson A
Sci Rep; 2022 Jan; 12(1):1185. PubMed ID: 35075155
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies.
Bennike T; Birkelund S; Stensballe A; Andersen V
World J Gastroenterol; 2014 Mar; 20(12):3231-44. PubMed ID: 24696607
[TBL] [Abstract][Full Text] [Related]
7. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
8. Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci.
Drobin K; Assadi G; Hong MG; Andersson E; Fredolini C; Forsström B; Reznichenko A; Akhter T; Ek WE; Bonfiglio F; Hansen MB; Sandberg K; Greco D; Repsilber D; Schwenk JM; D'Amato M; Halfvarson J
Inflamm Bowel Dis; 2019 Jan; 25(2):306-316. PubMed ID: 30358838
[TBL] [Abstract][Full Text] [Related]
9. High-Throughput Characterization of Blood Serum Proteomics of IBD Patients with Respect to Aging and Genetic Factors.
Di Narzo AF; Telesco SE; Brodmerkel C; Argmann C; Peters LA; Li K; Kidd B; Dudley J; Cho J; Schadt EE; Kasarskis A; Dobrin R; Hao K
PLoS Genet; 2017 Jan; 13(1):e1006565. PubMed ID: 28129359
[TBL] [Abstract][Full Text] [Related]
10. Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles.
Andersson E; Bergemalm D; Kruse R; Neumann G; D'Amato M; Repsilber D; Halfvarson J
PLoS One; 2017; 12(10):e0186142. PubMed ID: 28982144
[TBL] [Abstract][Full Text] [Related]
11. Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse.
Borren NZ; Plichta D; Joshi AD; Bonilla G; Sadreyev R; Vlamakis H; Xavier RJ; Ananthakrishnan AN
Inflamm Bowel Dis; 2020 Sep; 26(10):1524-1532. PubMed ID: 32766830
[TBL] [Abstract][Full Text] [Related]
12. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.
Verstockt S; Verstockt B; Machiels K; Vancamelbeke M; Ferrante M; Cleynen I; De Hertogh G; Vermeire S
Inflamm Bowel Dis; 2021 Oct; 27(10):1564-1575. PubMed ID: 33624092
[TBL] [Abstract][Full Text] [Related]
13. Serum biomarkers confirming stable remission in inflammatory bowel disease.
Kessel C; Lavric M; Weinhage T; Brueckner M; de Roock S; Däbritz J; Weber J; Vastert SJ; Foell D
Sci Rep; 2021 Mar; 11(1):6690. PubMed ID: 33758351
[TBL] [Abstract][Full Text] [Related]
14. Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic Perspective.
Wasinger VC; Yau Y; Duo X; Zeng M; Campbell B; Shin S; Luber R; Redmond D; Leong RW
Mol Cell Proteomics; 2016 Jan; 15(1):256-65. PubMed ID: 26530476
[TBL] [Abstract][Full Text] [Related]
15. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.
Bjerrum JT; Steenholdt C; Ainsworth M; Nielsen OH; Reed MA; Atkins K; Günther UL; Hao F; Wang Y
BMC Med; 2017 Oct; 15(1):184. PubMed ID: 29032767
[TBL] [Abstract][Full Text] [Related]
16. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay.
Cao Y; Dai Y; Zhang L; Wang D; Yu Q; Hu W; Wang X; Yu P; Ping Y; Sun T; Sang Y; Liu Z; Chen Y; Tao Z
Clin Biochem; 2022 Feb; 100():35-41. PubMed ID: 34843732
[TBL] [Abstract][Full Text] [Related]
17. Systemic Inflammation in Preclinical Ulcerative Colitis.
Bergemalm D; Andersson E; Hultdin J; Eriksson C; Rush ST; Kalla R; Adams AT; Keita ÅV; D'Amato M; Gomollon F; Jahnsen J; ; Ricanek P; Satsangi J; Repsilber D; Karling P; Halfvarson J
Gastroenterology; 2021 Nov; 161(5):1526-1539.e9. PubMed ID: 34298022
[TBL] [Abstract][Full Text] [Related]
18. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803
[TBL] [Abstract][Full Text] [Related]
19. New serological biomarkers of inflammatory bowel disease.
Li X; Conklin L; Alex P
World J Gastroenterol; 2008 Sep; 14(33):5115-24. PubMed ID: 18777587
[TBL] [Abstract][Full Text] [Related]
20. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
